Evidence map›Paper›PMID 41438056›Full record

ArticleiScience2025

Uncovering cantharidin's mechanism for cholangiocarcinoma treatment using patient-derived tumor organoids.

Pinsheng Han, Libo Wang, Liuyang Zhu, Wen Tong, Sen Liu, Tianze Wang, Tianrun Yang, ZhenZhen Li, Xiaolei Zhou, Tianyu Zhao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pinsheng HanSchool of Medicine, Nankai University, Tianjin 300071, China.
Libo WangState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Liuyang ZhuDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300384, China.
Wen TongFirst Central Hospital of Tianjin Medical University, Tianjin 300192, China.
Sen LiuDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China.
Tianze WangSchool of Medicine, Nankai University, Tianjin 300071, China.
Tianrun YangFirst Central Hospital of Tianjin Medical University, Tianjin 300192, China.
ZhenZhen LiState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Xiaolei ZhouState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Tianyu ZhaoState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Tao CuiHefei Tianhui Biotechnology Co., Ltd., Hefei 230000, China.
Long YangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300384, China.
Ze WangState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300384, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the antitumor efficacy of cantharidin against cholangiocarcinoma (CCA) using patient-derived organoids (PDOs) that faithfully replicate the histological and genomic features of original tumors. Results demonstrate that cantharidin effectively inhibits CCA PDO growth, showing comparable or superior efficacy to conventional chemotherapeutics such as cisplatin, though slightly less potent than gemcitabine or Adriamycin. Critically, drug sensitivity in PDOs correlated perfectly with clinical responses in five patients, validating the model's predictive relevance. Mechanistic studies revealed that cantharidin suppresses proliferation and induces apoptosis primarily through downregulation of the p-ERK1/2-c-Fos signaling pathway, both

Indexed as

CancerClinical pharmacyTherapy

Identifiers

PMID41438056
PMCPMC12719768

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.